Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

Wanbury reports 88% drop in Q3 FY25 PAT

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25

GSK's Nucala application for COPD accepted for review in China

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved

Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

KIMS partners with UAIMS Hospital

This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years